-
Cell milestone: PD-1 can't treat brain tumors. This target is interesting
Time of Update: 2021-03-24
In this study, the researchers used single-cell RNA-seq technology to analyze tumor-infiltrating T cells from fresh tumor samples from 31 glioma patients to map the gene expression of these T cells.
"To sum up, our research shows that CD161-CLEC2D is a new potential target for diffuse glioma immunotherapy.
-
Yuandong, Koxing... 26 pharmaceutical companies "snatching the beach" section of the board 36 on the road
Time of Update: 2021-03-24
com, China Securities Regulatory Commission, Shanghai Stock Exchange official website, company announcement Medical News, February 25, July 2019, the highly-regarded Sci-tech Innovation Board started to open, detonating the A-share market.
-
49 batches of drugs are unqualified
Time of Update: 2021-03-24
The 49 batches of drugs found in the fourth phase of drug quality random inspections in 2020 that do not meet the standards and regulations are now announced (see the attachment for details).
-
International Rare Disease Day|The success rate of clinical development of rare disease drugs in the past 10 years is 17%
Time of Update: 2021-03-24
According to the latest report on the success rate of drug clinical development: From 2011 to 2020, the average success rate of rare disease (excluding tumor indications) drugs from phase 1 clinical trials to the approval of the US FDA for marketing is 17.
-
Vaccines | Two more new crown vaccines are on the market to check the current status of domestic COVID-19 vaccine research and development
Time of Update: 2021-03-24
On February 25, the State Food and Drug Administration conditionally approved the new coronavirus inactivated vaccine (Vero cell) of Sinopharm Wuhan Institute of Biological Products and the recombinant new coronavirus vaccine (type 5 adenovirus vector) of Cansino Bio Application for registration of a new crown vaccine.
-
Cancer immunotherapy "veteran" IL-2: Can the resurgence of research and development continue to write the PD-1 myth?
Time of Update: 2021-03-24
A variety of engineering IL-2One of the core challenges of converting IL-2 into anti-cancer therapy is cell specificity: Since IL-2 can promote the proliferation of effector T cells and regulatory T cells, is it possible to activate one of them preferentially What about the T cell population?In order to achieve this goal, scientists have been studying the structure of IL-2 receptors for more than a decade.
-
Zuoli Pharmaceutical Co., Ltd.: Coji Pharmaceutical Co., Ltd., a joint stock company, submits a listing application to the Hong Kong Stock Exchange
Time of Update: 2021-03-24
, a joint stock company, CARsgenTherapeutics Holdings Limited (hereinafter referred to as "Keji Pharmaceutical"), issued a transaction to the Hong Kong Stock Exchange on February 26, 2021.
On the same day, the website of the Hong Kong Stock Exchange published the application materials for the issuance and listing of Keji Pharmaceutical.
-
Sanofi and Johnson & Johnson reached a partnership to assist in the production of a new crown pneumonia vaccine
Time of Update: 2021-03-24
Not long before it reached a vaccine cooperation with Johnson & Johnson, Sanofi announced a partnership with Pfizer and BioNTech to assist the two companies in the production of 100 million doses of mRNA vaccines.
-
2021 The first wave of salary adjustment plans for pharmaceutical companies is coming!
Time of Update: 2021-03-24
However, in addition to the good news of the salary increase, there is also news that Huizhi reduced the county travel subsidy from 2,600 to 1,150 in February this year.
In addition to salary increases, it is reported that this year, pharmaceutical companies have announced salary cuts.
-
Behind the sharp correction, we are still optimistic about the chain pharmacy track!
Time of Update: 2021-03-24
Regarding the standard retail industry, taking into account the professionalism and strict supervision of pharmaceutical products (see "The medical e-commerce is here, are chain pharmacies still a good track?"), we It is predicted that the penetration rate of the entire pharmaceutical e-commerce company will not exceed 30% in the next two decades.
-
Canley Announces Approval of U.S. Clinical Trial Application for THR-β Agonist ASC41 NASH Indication
Time of Update: 2021-03-24
The approval of the US clinical trial application (IND) is based on a randomized, double-blind, placebo-controlled, single-dose and multi-dose escalation phase I clinical trial with 65 subjects completed in China Efficacy and safety data, as well as the process data of oral tablets developed by Ganlai’s proprietary formulation technology that can be produced commercially.
-
Aber Maintenance Meile is approved by the FDA for the treatment of children with moderate to severe active ulcerative colitis
Time of Update: 2021-03-24
Compile Ke KeOn February 24, AbbVie announced that the US FDA approved Humira (Adalimumab, trade name Humira) for the treatment of moderate to severe active ulcerative colitis (UC) in children aged 5 years and older.
-
Is presbyopia saved?
Time of Update: 2021-03-24
AGN-190584 is an improved new drug formulation of pilocarpine (a cholinergic muscarinic receptor agonist), which was developed as a once-daily eye drop for the treatment of presbyopia.
If AGN-190584 can be approved, it will be the first eye drop for the treatment of presbyopia, which can provide new treatment options for American patients.
-
The new version of the medical insurance catalog is launched, and 119 drugs can be reimbursed from March 1st
Time of Update: 2021-03-24
" said Nie Guangmeng, director of the medical insurance office of Beijing Tsinghua Chang Gung Memorial Hospital, in order to let patients enjoy The latest medical insurance reimbursement policy, the hospital pharmnet.
-
The 2020 transcripts of 241 pharmaceutical companies are released!
Time of Update: 2021-03-24
Regarding the substantial growth in performance, Yiling Pharmaceutical said that on the one hand, the brand awareness of the company's Lianhua Qingwen products has been greatly improved, the domestic market demand has increased significantly, and sales have also been achieved in more than ten registered overseas countries.
-
AstraZeneca withdraws U.S. eligibility for imfinzi bladder cancer indication
Time of Update: 2021-03-24
At that time, there was an analysis that the FDA may re-examine Imfinzi's previous accelerated approval for the second-line indication of bladder cancer.
-
National Health and Wellness Commission: disposable medical supplies or was transferred out of the catalog!
Time of Update: 2021-03-24
For those that cannot be reused, they should try their best to choose corresponding alternative products or materials to avoid setting unreasonable technical barriers; The second is to cooperate with the drug regulatory department to strengthen research and demonstration, and to support the reuse of clinical norms that can be reused in the diagnosis and treatment process and can be guaranteed to be safe and effective, not included in the catalog of single-use medical devices.
-
The off-season for a batch of medicine sales is here
Time of Update: 2021-03-24
As a manufacturing company, we did not relax the prevention and control of the epidemic during the Spring Festival.
Fight the first battle of post-holiday salesThe Spring Festival has passed and normal sales are about to begin.
-
The crime of "drug regulatory malfeasance" is coming today
Time of Update: 2021-03-24
On February 27, the official website of the Supreme People's Procuratorate issued the "Supplementary Provisions on the Implementation of the Criminal Law of the People's Republic of China on Determining Crimes (7)" (hereinafter referred to as the "Supplementary Provisions").
-
National Health Commission: Occupational disease diagnosis should be concluded within 30 days from the receipt of all materials
Time of Update: 2021-03-24
Medical News February 23 The new version of "Occupational Disease Diagnosis and Appraisal Management Measures" is here The diagnostic agency shall make a diagnosis within 30 days from the receipt o
